Multiple Choice Assessment Questions

1. Once a person reaches 65 years of age, his/her risk for Alzheimer’s disease doubles every _____ years.
   a. 3
   b. 10
   c. 5
   d. 8

2. Which chromosomes contain genes for proteins that may affect amyloid precursor protein (APP) processing?
   a. Chromosome 1 and 19
   b. Chromosome 19 and 21
   c. Chromosome 1 and 14
   d. Chromosome 14 and 19

3. Which central neurotransmitters are affected by Alzheimer’s disease?
   a. Acetylcholine
   b. Norepinephrine
   c. Glutamate
   d. All of the above

4. Which of the following are risk factors for Alzheimer’s disease?
   a. Hypertension and high triglycerides
   b. Age and head trauma
   c. Family history and history of tobacco use
   d. Diabetes and history of ethanol use

5. A patient was just diagnosed with Alzheimer’s disease. Based on average survival after diagnosis, the patient will likely live for how many more years?
   a. 1 more year
   b. 12 more years
   c. 5 more years
   d. 2 more years

6. Which APOE isoform is most highly associated with an increased risk for developing late-onset Alzheimer’s disease?
   a. APOE*2
   b. APOE*3
   c. APOE*4
   d. None, the APOE gene is associated with early-onset Alzheimer’s disease
7. Which of the following is true regarding mild cognitive impairment (MCI)?
   a. Seventy-five percent of Americans over age 60 are affected by mild cognitive impairment.
   b. Mild cognitive impairment always progresses to Alzheimer’s disease.
   c. Mild cognitive impairment should be treated with cholinesterase inhibitors.
   d. A patient who is affected by mild cognitive impairment has more cognitive impairment that would be expected for their age, but it is not severe enough to be considered dementia.

8. Which of the following conditions can affect a patient’s cognitive function and produce dementia-like symptoms?
   a. Infections
   b. Stroke
   c. Metabolic disorders
   d. All of the above

9. Which of the following agents is not commonly used due to its potential to cause hepatotoxicity?
   a. Rivastigmine
   b. Tacrine
   c. Galantamine
   d. Memantine

10. Which of the following medications will improve cognitive function in a patient with Alzheimer’s disease?
    a. Benadryl®
    b. Memantine
    c. Valproate
    d. Duloxetine

11. Which of the following medications are currently approved for the treatment of Alzheimer’s disease?
    a. Gingko biloba
    b. Atorvastatin (HMG CoA reductase inhibitor)
    c. Razadyne®
    d. Buspar®

12. Which of the following medications are specifically approved for the treatment of moderate to severe forms of Alzheimer’s disease?
    a. Aricept® and Namenda®
    b. Tacrine and galantamine
    c. Memantine and rivastigmine
    d. Exelon® and Aricept®

13. Which of the cholinesterase inhibitors also acts to activate nicotinic type receptors at a separate site?
    a. Aricept®
    b. Namenda®
    c. Exelon®
    d. Razadyne®
14. Which of the following medications acts on N-methyl-N-aspartate (NMDA) glutamate receptors?
   a. Galantamine
   b. Rivastigmine
   c. Memantine
   d. Tacrine

15. Which of the following medication classes is under investigation for the treatment of Alzheimer’s
disease and is also approved for the treatment of depression, which Alzheimer’s disease patients may
develop?
   a. Tricyclic antidepressants (TCAs)
   b. Selective serotonin reuptake inhibitors (SSRIs)
   c. Monoamine oxidase inhibitors (MAO-Is)
   d. Selective norepinephrine reuptake inhibitors (SNRIs)

16. A patient that has lost psychomotor skills, lost the ability to speak and communicate effectively, and is
completely dependent upon their caretaker falls into what category of cognitive decline?
   a. Mild
   b. Moderate/Severe
   c. Severe
   d. Very severe

17. What is the main goal of therapy for a patient being treated for Alzheimer’s disease?
   a. Treat the patient’s symptoms
   b. Reverse the patient’s cognitive decline
   c. Maintain the patient’s independence
   d. Effectively treat psychiatric and behavioral complications
   e. Manage financial costs of the patient’s therapy

To receive continuing education credit, please note the following information:
1. Complete the participant information in the spaces provided. Use BLUE ink only.
2. Mail the completed form for scoring to the address listed below. The quiz must be postmarked by the
expiration date. Faxed CE quizzes WILL NOT be accepted.
   Mail to: APA, 1211 Carmichael Way, Montgomery, AL  36106
3. CE processing is free for APA members. Non-members must include a processing fee of $20 per quiz.
4. No more than 3 quizzes will be accepted per month per individual.
5. Credit will be awarded for a passing grade of 80% or better. If you fail the exam, you may retake it once,
and corrected answers must be in RED ink.
Participant Information:

AL License #______________

Name___________________________________________________

Address__________________________________________________

City______________________________State_____ Zip__________

E-mail___________________________________________________

NABP e-Profile #__________________________________________

MM/DD (month/day of birth)_______________________________

How long did it take you to read the program and complete this test?

__________ hours   __________ minutes

My signature certifies that I have independently taken this CE examination.

________________________________________________________

CE Assessment Answers
Please circle your answers (one answer per question).

1.   A  B  C  D

2.   A  B  C  D

3.   A  B  C  D

4.   A  B  C  D

5.   A  B  C  D

6.   A  B  C  D

7.   A  B  C  D

8.   A  B  C  D

9.   A  B  C  D

10.  A  B  C  D

11.  A  B  C  D

12.  A  B  C  D

13.  A  B  C  D

14.  A  B  C  D

15.  A  B  C  D

16.  A  B  C  D

17.  A  B  C  D  E

Program Evaluation - Must be completed for credit.

Please rate the following items on a scale from 1 (poor) to 4 (excellent).
1. Overall quality of the article   1  2  3  4
2. Relevance to pharmacy practice  1  2  3  4
3. Value of the content            1  2  3  4

Please answer each question, marking whether you agree or disagree.
4. This course met the learning objectives.  □ Agree  □ Disagree

Impact of the Activity
The information presented (check all that apply):
5. □ Reinforced my current practice/treatment habits
    □ Will improve my practice/patient outcomes
    □ Provided new ideas or information I expect to use
    □ Adds to my knowledge

6. Will the information presented cause you to make any changes in how you do your job? □ Yes  □ No

7. How committed are you to making these changes?
   (Not committed) 1  2  3  4 (Very committed)

8. Do you feel future activities on this subject matter are necessary and/or important? □ Yes  □ No

Follow-Up
As part of our ongoing quality-improvement effort, we would like to be able to contact you in the event we conduct a follow-up survey to assess the impact of our educational interventions on professional practice. Are you willing to participate in such a survey? □ Yes  □ No